Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4–5 years after a previous dose
| Autor: | Shelly Senders, Thomas Latiolais, Marc Dionne, Joanne M. Langley, Francisco Noya, Scott A. Halperin, William Meekison, David R. Johnson, Roehl Johnson, Shelly A. McNeil, Mark M. Blatter, Paul Zickler, Joanne Embree |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Canada Pediatrics medicine.medical_specialty Diphtheria vaccine Adolescent Fever Immunization Secondary Pain Booster dose Diphtheria-Tetanus-acellular Pertussis Vaccines complex mixtures Young Adult medicine Humans Fatigue Aged General Veterinary General Immunology and Microbiology Tetanus business.industry Diphtheria Headache Public Health Environmental and Occupational Health Toxoid Middle Aged medicine.disease Antibodies Bacterial Virology United States Infectious Diseases Erythema Tetanus vaccine Molecular Medicine Pertussis vaccine Female Antitoxins business medicine.drug |
| Zdroj: | Vaccine. 29:8459-8465 |
| ISSN: | 0264-410X |
| Popis: | Background Although decennial adult boosters of tetanus and diphtheria toxoids are recommended in Canada and the United States, a second dose of pertussis vaccine is not currently recommended for adults. Methods This open-label, postmarketing, multicenter study evaluated the tolerability and immunogenicity of a second dose of an adult formulation of tetanus, diphtheria, and pertussis vaccine (Tdap) in adolescents and adults 5 years after a first dose. Results A total of 545 participants from previous Tdap vaccine studies, ranging in age from 15 to 69 years, participated in this study. Of these participants, 94.2% had at least one solicited adverse event after the booster dose such as injection-site erythema (28.6%), swelling (25.6%), or pain (87.6%) or a systemic adverse event such as myalgia (61.0%), headache (53.2%), malaise (38.2%), or fever (6.5%). These adverse events were slightly more frequent than after the initial dose. Postvaccination, 100% of participants had a tetanus antibody level ≥0.10 IU/mL and 95% had a diphtheria antibody level ≥0.10 IU/mL. For pertussis, 82.1% (pertussis toxoid), 96.7% (filamentous hemagglutinin), 95.6% (pertactin), and 99.8% (fimbriae) had a postvaccination antibody threshold of ≥50 EU/mL. Conclusion A second dose of Tdap vaccine 5 years after the initial dose was well tolerated and immunogenic in adolescents and adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect